“The topics in these calls show how IHI makes concrete contributions to key European policies. Our two topics on the environmental impacts of healthcare are in line with the goals of the European Green Deal. We have topics that advance the EU’s aim of replacing, reducing and refining the use of animals in research. We also have a topic that will help to boost the involvement of people from underserved patient populations in clinical trials.” said IHI’s interim Executive Director, Dr Hugh Laverty.

Today we publish a White Paper outlining how EFPIA member companies are actively engaged – on site and along the value chain – in groundbreaking and ambitious projects to rise to the challenges posed by climate change.

Beyond case studies, you will find the outcomes of an internal survey conducted in 2022 that highlights the pharmaceutical industry's commitments to making a positive impact on the lives of patients, while operating sustainably.

In 2014, EFPIA and PhRMA published their Principles for Responsible Clinical Trial Data Sharing, demonstrating the industry’s commitment to support innovation and to comply with and go beyond the legal requirements of clinical trial data sharing. In 2023, to reflect the evolution of EFPIA and PhRMA member company practices, we have revised the wording of these principles.

Read the updated version here.